HH Biotechnology Holdings Company

Total Valuation

HH Biotechnology Holdings Company carries a market capitalization of 1,406.00, placing it among publicly traded companies globally. Its enterprise value stands at 39.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

HH Biotechnology Holdings Company currently has 14.06M shares outstanding.

Valuation Ratios

HH Biotechnology Holdings Company trades at a trailing price-to-earnings ratio of 14.90. The price-to-sales ratio is 5.39, and the price-to-book ratio stands at 2.98.

Enterprise Valuation

On an enterprise value basis, HH Biotechnology Holdings Company trades at an EV/EBITDA multiple of 5.84 and an EV/FCF ratio of 7.91. The EV/Sales ratio of 4.98 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.88 provides insight into valuation relative to core operating earnings.

Financial Position

HH Biotechnology Holdings Company maintains a current ratio of 0.34, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

HH Biotechnology Holdings Company posts a return on equity of 22.83 and a return on invested capital of 7.19.

Taxes

Over the trailing twelve months, HH Biotechnology Holdings Company has paid 1.06M in income taxes, reflecting an effective tax rate of 28.00.

Stock Price Statistics

HH Biotechnology Holdings Company's stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Income Statement

Over the trailing twelve months, HH Biotechnology Holdings Company generated 7.95M in revenue and converted that into 2.88M in net income, yielding earnings per share of 0.19. EBITDA reached 6.78M, while operating income came in at 3.64M.

Balance Sheet

Total book value stands at 14.41M, with working capital of -8.70M providing operational flexibility.

Cash Flow

HH Biotechnology Holdings Company produced 4.84M in operating cash flow over the past twelve months. After subtracting -22,551.00 in capital expenditures, free cash flow totaled 4.82M - equivalent to 0.34 per share.

Margins

HH Biotechnology Holdings Company operates with a gross margin of 34.84, reflecting its pricing power and cost economics. The operating margin of 45.78 and net profit margin of 36.19 provide insight into operational efficiency.

Dividends & Yields

Scores

HH Biotechnology Holdings Company posts an Altman Z-Score of 2.65, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.